(TheNewswire)
Calgary, Canada - TheNewswire - December 14, 2023 - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovativemedical imaging solutions, is pleased to announce the formalization ofa pivotal sales and distribution alliance with an internationallyrecognized pharmaceutical distribution company in Central America.This landmark agreement marks a significant milestone in Voyageur'sjourney, signaling its entry into the global market.
This strategic partnership is a testament to Voyageur'sunwavering commitment to excellence and innovation. It grants thedistributor exclusive rights within their designated territory,acknowledging their key role in securing regulatory licensing forVoyageur's suite of five barium contrast products. Given thesensitivity and competitive nature of the barium contrast market,Voyageur remains steadfast in maintaining strict confidentialityregarding client information, pricing, and sales volumes.
Anticipating a pivotal launch in the first half of2024, Voyageur is poised to unveil its comprehensive suite of fiveHealth Canada licensed barium contrast products. These innovativeproduct solutions play a vital role in diagnosing diseases, disorders,and abnormalities throughout the digestive system, and are seamlesslyintegrated with X-ray and computed tomography (CT scan)procedures.
Brent Willis, CEO of Voyageur, expressed his enthusiasmstating, "We are in active discussions with multiple distributorsand clients both domestically and internationally in preparation forour imminent product launch. Concurrently, we are meticulouslyadvancing the formulation and rigorous testing of our full suite ofproducts, prioritizing quality and efficacy. The forthcoming revenuefrom sales will significantly contribute to advancing the FrancesCreek barium sulfate project, contingent upon securingfinancing.
The Frances Creek barium sulfate project holdssignificant potential, underscored by a Preliminary EconomicAssessment (PEA) valuing it at an NPV of $344 million and projecting$839 million of pre-tax revenue over the next decade. https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-announces-irr-of-137-npv-of-344-million-from-preliminary-economic-assessment-for-the-frances-creek-pharmaceutical-barium-project/ Importantly, Voyageur stands out as one of the few providersof commercial natural pharmaceutical-grade barium sulfate on a globalscale. Currently importing synthetic man-made barium sulfate to meetmarket demands, Voyageur anticipates a substantial reduction in bariumcosts upon the successful production of Frances Creek bariumsulfate.
Looking ahead, Voyageur remains committed torevolutionize medical imaging solutions, generating substantial valuefor its shareholders. The Company appreciates your continued supportas it embarks on this transformative phase of growth and marketexpansion.
About Voyageur PharmaceuticalsLtd.
Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium,iodine and carbon Active Pharmaceutical Ingredients (API) andhigh-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium, iodine andcarbon contrast imaging market, Voyageur aims tobecome a key player by producing its own barium, iodine, and fullereneminerals.
Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As the Corporation solidifies itspresence in the market, it will transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.
Voyageur is committed to sustainability andenvironmental stewardship. The Corporation envisions a future wherecarbon neutrality is the norm, and to achieve this, it plans to buildstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, itaims to become 100% carbon neutral across all its manufacturingactivities. Voyageur's commitment to the environment sets it apart asa pioneer in the industry.
At the core of the Corporation's operations, Voyageurowns a 100% interest in two barium sulphate (barite) projects,including the Frances Creek and Pedley Mountain properties.Additionally, Voyageur holds interests in a high-grade iodine,lithium, and bromine brine project situated in Utah, USA, furtherbolstering its position in the industry. Voyageur also owns a 100%interest in two battery mineral projects which focus on copper/zincdevelopment.
Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the imaging contrastmedia drug market. By controlling all primary input costs, from thesourcing of raw materials to final production, it plans to ensureunmatched quality and cost efficiency. Voyageur embodies the motto of" From the Earth to theBottle ," highlighting its commitment toresponsible sourcing and manufacturing practices.
For Further Information:
Brent Willis, CEO, | Albert Deslauriers, CFO, |
Brent@vpharma.ca | Albert@vpharma.ca |
info@vpharma.ca | https://voyageurpharmaceuticals.ca/ |
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Cautionary Statement Regarding “Forward-Looking”Information
This news release may contain certainforward-looking information and statements, including withoutlimitation, statements pertaining to the success of the distributioncompany in obtaining the regulatory licensing and sales of Voyageur'sproducts in the designated territory, the success of the launch of itsbarium contrast products in Canada, the success of the Francis Creekbarium sulfate project, and Voyageur's plans to become self sufficientand vertically integrated, and other statements herein, whichexpressly or impliedly speak to Voyageur's expectations for itsbusiness and operations. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties, including,without limitation, global market factors and supply chain issues,risks relating to the regulation and approval of Voyageur's products,and generalrisks relating to Voyageur's business. There can be no assurance thatsuch information will prove to be accurate, and actual results andfuture events could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR+ website at www.sedarplus.ca. Voyageur does not undertake toupdate any forward-looking information except in accordance withapplicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.